Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Market Cap | Price | Price Target | Upside/Downside | Top Analysts Upside/Downside | Consensus | Top Analysts Consensus | Analysts | Top Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GYRE | GYRE THERAPEUTICS INC | $712.68M | $7.35 | N/A | N/A | N/A | N/A | 47.93% | 194.54% | 62.50% | 39.89% | |||
| SLNO | SOLENO THERAPEUTICS INC | $2.72B | $52.78 | $61.17 | 15.89% | Hold | 6 | 96.59% | 308.74% | 107.66% | 85.95% | |||
| ADMA | ADMA BIOLOGICS INC | $2.52B | $10.60 | $22.50 | 112.26% | Strong Buy | 2 | 23.62% | 37.72% | 109.42% | 83.67% | |||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $39.94B | $301.19 | $457.71 | 51.97% | Strong Buy | 17 | 34.28% | 79.14% | 338.79% | 53.84% | |||
| ZVRA | ZEVRA THERAPEUTICS INC | $567.74M | $9.67 | $23.67 | 144.75% | Strong Buy | 3 | 42.94% | 22.23% | 124.68% | 67.72% | |||
| CORT | CORCEPT THERAPEUTICS INC | $4.96B | $46.59 | $88.33 | 89.60% | Buy | 3 | 24.38% | 46.21% | 102.67% | 79.50% | |||
| HALO | HALOZYME THERAPEUTICS INC | $7.44B | $63.06 | $83.00 | 31.62% | Buy | 6 | 16.34% | 60.02% | 2,340.27% | 45.24% | |||
| KRYS | KRYSTAL BIOTECH INC | $7.60B | $259.95 | $326.25 | 25.50% | Strong Buy | 8 | 34.87% | 27.99% | 62.02% | 56.71% | |||
| NAGE | NIAGEN BIOSCIENCE INC | $381.18M | $4.76 | $13.00 | 173.11% | Strong Buy | 1 | 17.44% | 30.72% | 53.36% | 38.38% | |||
| RPRX | ROYALTY PHARMA PLC | $28.55B | $49.49 | $53.75 | 8.61% | Strong Buy | 4 | 16.61% | 50.65% | 42.64% | 21.11% | |||
| VCEL | VERICEL CORP | $1.70B | $33.43 | $53.00 | 58.54% | Strong Buy | 2 | 18.40% | 57.28% | 22.34% | 16.23% | |||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $1.80B | $31.05 | $44.00 | 41.71% | Buy | 6 | 14.72% | 21.56% | 21.79% | 14.91% | |||
| MNKD | MANNKIND CORP | $847.28M | $2.75 | $7.42 | 169.71% | Buy | 6 | 15.77% | 136.88% | -92.39% | 5.95% | |||
| APLS | APELLIS PHARMACEUTICALS INC | $5.23B | $40.95 | $36.53 | -10.79% | Buy | 15 | 6.37% | 64.38% | 48.18% | 16.59% | |||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $4.08B | $52.99 | $62.20 | 17.38% | Strong Buy | 5 | 18.67% | 32.59% | 39.09% | 28.69% | |||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $10.43B | $54.21 | $85.31 | 57.37% | Strong Buy | 13 | 12.23% | 58.02% | 28.66% | 22.97% | |||
| EXEL | EXELIXIS INC | $11.61B | $44.69 | $45.13 | 0.97% | Hold | 8 | 12.73% | 19.19% | 60.81% | 46.21% | |||
| LGND | LIGAND PHARMACEUTICALS INC | $4.48B | $224.86 | $249.71 | 11.05% | Strong Buy | 7 | 11.10% | 32.75% | 22.50% | 14.66% | |||
| TECH | BIO-TECHNE CORP | $8.13B | $51.95 | $71.71 | 38.04% | Strong Buy | 7 | 6.03% | 69.48% | 19.68% | 15.69% | |||
| REGN | REGENERON PHARMACEUTICALS INC | $71.96B | $686.36 | $862.79 | 25.71% | Strong Buy | 19 | 8.99% | 13.89% | 22.53% | 17.33% | |||
| VRTX | VERTEX PHARMACEUTICALS INC | $107.52B | $423.24 | $547.60 | 29.38% | Strong Buy | 20 | 10.98% | 18.71% | 40.38% | 29.39% | |||
| CPRX | CATALYST PHARMACEUTICALS INC | $3.45B | $28.26 | $35.00 | 23.85% | Strong Buy | 1 | 9.45% | 8.54% | 60.44% | 52.24% | |||
| VCYT | VERACYTE INC | $2.53B | $31.78 | $43.83 | 37.93% | Buy | 6 | 12.19% | 19.12% | 12.54% | 11.68% | |||
| UTHR | UNITED THERAPEUTICS CORP | $25.03B | $571.07 | $623.67 | 9.21% | Buy | 9 | 11.80% | 9.62% | 30.55% | 27.51% | |||
| XOMA | XOMA ROYALTY CORP | $488.01M | $40.99 | $67.00 | 63.45% | Strong Buy | 4 | 14.75% | 2.94% | N/A | N/A | |||
| INCY | INCYTE CORP | $19.80B | $99.10 | $109.57 | 10.57% | Buy | 14 | 7.03% | 9.91% | 13.39% | 10.26% | |||
| MDXG | MIMEDX GROUP INC | $458.33M | $3.09 | $8.40 | 172.29% | Strong Buy | 5 | 1.87% | 0.52% | 21.26% | 15.92% | |||
| PBYI | PUMA BIOTECHNOLOGY INC | $380.56M | $7.48 | N/A | N/A | N/A | N/A | -0.89% | 2.26% | 19.91% | 12.00% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.